Literature DB >> 20145123

Tumor suppressor HLJ1 binds and functionally alters nucleophosmin via activating enhancer binding protein 2alpha complex formation.

Tzu-Pei Chang1, Sung-Liang Yu, Sheng-Yi Lin, Yi-Jing Hsiao, Gee-Chen Chang, Pan-Chyr Yang, Jeremy J W Chen.   

Abstract

HLJ1, a member of the heat shock protein 40 chaperone family, is a newly identified tumor suppressor that has been implicated in tumorigenesis and metastasis in non-small cell lung cancer. However, the mechanism of HLJ1 action is presently obscure. In this study, we report that HLJ1 specifically interacts with the nuclear protein nucleophosmin (NPM1), forming a multiprotein complex that alters the nucleolar distribution and oligomerization state of NPM1. Enforced accumulation of NPM1 oligomers by overexpression in weakly invasive but high HLJ1-expressing cells induced the activity of signal transducer and activator of transcription 3 (STAT3) and increased cellular migration, invasiveness, and colony formation. Furthermore, silencing HLJ1 accelerated NPM1 oligomerization, inhibited the activity of transcription corepressor activating enhancer binding protein 2alpha (AP-2alpha), and increased the activities of matrix metalloproteinase-2 (MMP-2) and STAT3. Our findings suggest that HLJ1 switches the role of NPM1, which can act as tumor suppressor or oncogene, by modulating the oligomerization of NPM1 via HLJ1-NPM1 heterodimer formation and recruiting AP-2alpha to the MMP-2 promoter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145123     DOI: 10.1158/0008-5472.CAN-09-2453

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.

Authors:  Tolga Acun; Natalie Doberstein; Jens K Habermann; Timo Gemoll; Christoph Thorns; Emin Oztas; Thomas Ried
Journal:  OMICS       Date:  2017-05

2.  A Targeted Proteomic Approach for Heat Shock Proteins Reveals DNAJB4 as a Suppressor for Melanoma Metastasis.

Authors:  Weili Miao; Lin Li; Yinsheng Wang
Journal:  Anal Chem       Date:  2018-05-11       Impact factor: 6.986

Review 3.  Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.

Authors:  Meng-Feng Tsai; Chi-Chung Wang; Jeremy Jw Chen
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling.

Authors:  Mikael S Lindström
Journal:  Biochem Res Int       Date:  2010-10-05

5.  HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Authors:  C-H Chen; W-H Chang; K-Y Su; W-H Ku; G-C Chang; Q-S Hong; Y-J Hsiao; H-C Chen; H-Y Chen; R Wu; P-C Yang; J J W Chen; S-L Yu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

6.  HLJ1 is a novel biomarker for colorectal carcinoma progression and overall patient survival.

Authors:  Yong Liu; Jie Zhou; Cuiwei Zhang; Wenguang Fu; Xiuli Xiao; Sibei Ruan; Yuan Zhang; Xia Luo; Mingxi Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

7.  DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1.

Authors:  Hye-Youn Kim; Young-Mi Kim; Suntaek Hong
Journal:  Cell Death Dis       Date:  2021-05-08       Impact factor: 8.469

8.  Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.

Authors:  Yan Liu; Fei Zhang; Xiao-Fang Zhang; Li-Sha Qi; Lei Yang; Hua Guo; Ning Zhang
Journal:  J Biomed Sci       Date:  2012-05-25       Impact factor: 8.410

9.  GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.

Authors:  Jee-Youn Kim; Young-Eun Cho; Yong-Min An; Sang-Hoon Kim; Yong-Gwan Lee; Jae-Hoon Park; Sun Lee
Journal:  J Cell Mol Med       Date:  2015-03-27       Impact factor: 5.310

10.  Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.

Authors:  L Lam; Z Aktary; M Bishay; C Werkman; C-Y Kuo; M Heacock; N Srivastava; J R Mackey; M Pasdar
Journal:  Oncogenesis       Date:  2012-03-19       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.